The grant of monopoly patent protection is justified normally as a means for giving incentive for innovation. Market driven innovation is not necessarily equitable, however, and the development concerns over the international intellectual property regime governing the products of medical...

Using a reduced form binary econometric model, we analyze the determinants of pharmaceutical companies entry decisions into new submarkets. Our sample includes data for pharmaceutical companies over the period 1987-1998 for seven countries. Estimation is done both at the aggregate level and at a...